P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials
Philippe Moreau,Keith Stewart,Meletios A. Dimopoulos,David S. Siegel,Thierry Facon,James R. Berenson,Noopur Raje,Jesus G. Berdeja,Robert Z. Orlowski,Hui Yang,Haijun Ma,Zandra Klippel,Anita Zahlten-Kumeli,Khalid Mezzi,Karim Iskander,Maria-Victoria Mateos +15 more
TL;DR: It is suggested that Kd70 QW has a comparable efficacy profile compared with Kd56 BIW and represents a convenient and well‐tolerated treatment for patients with RRMM.
Journal ArticleDOI
Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
Diana Cortes-Selva,Tineke Casneuf,Deeksha Vishwamitra,Sarah Stein,Tatiana Perova,Sheri Skerget,Elena Ramos,L. van Steenbergen,Dries De Maeyer,Rengasamy Boominathan,Onsay Lau,Cuc Davis,Arnob Banerjee,Tara Stephenson,Clarissa M. Uhlar,Rachel Kobos,Jenna D. Goldberg,Lixia Pei,D. Trancucci,Suzette Girgis,S. X. Wang Lin,Liviawati Wu,Philippe Moreau,Saad Usmani,Nizar J. Bahlis,N. W. C. J. van de Donk,Raluca I. Verona +26 more
TL;DR: The MajesTEC-1 study as mentioned in this paper investigated the safety/efficacy of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM) who previously received ≥3 lines of therapy.
Journal ArticleDOI
Ixazomib in the management of relapsed multiple myeloma
Cyrille Touzeau,Philippe Moreau +1 more
TL;DR: The present review addresses the current knowledge regarding the clinical use of ixazomib in relapsed myeloma patients and approved in combination with lenalidomide and dexamethasone.
Journal Article
Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma.
Philippe Moreau,Francoise Mechinaud,Béatrice Mahé,S. Le Tortorec,M. J. Rapp,Hervé Maisonneuve,J-L Harousseau,Noel-Jean Milpied +7 more
TL;DR: For selected patients with HLA-identical siblings and good performance status who relapse after autologous transplantation for high-grade non-Hodgkin's lymphoma, allogeneic BMT may be an option.
Journal ArticleDOI
Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK.
Carole Brosseau,Christelle Dousset,Cyrille Touzeau,Sophie Maïga,Philippe Moreau,Martine Amiot,S. Le Gouill,Catherine Pellat-Deceunynck +7 more
TL;DR: Preclinical data provide the rationale to investigate the role of VD3 in vivo in the response to Len, and confirm the direct involvement of Bik in cell death.